Osteoporosis International

, Volume 21, Supplement 2, pp 407–413 | Cite as

Development and use of FRAX® in osteoporosis

  • J. A. Kanis
  • E. V. McCloskey
  • H. Johansson
  • A. Oden
  • O. Ström
  • F. Borgström


This paper reviews briefly the development and clinical use of FRAX® in the development of assessment guidelines for osteoporosis.

Fractures are the clinical consequence of osteoporosis and are a major cause of morbidity and mortality worldwide. Several treatments are available that have been shown to decrease the risk of fracture, but problems arise in identifying individuals at high fracture risk so that treatments can be effectively targeted. Case finding can be enhanced by the consideration of clinical risk factors that provide information on fracture risk over and above that provided by bone mineral density measurements. The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk.


Case finding Clinical guidelines Fracture probability FRAX Intervention threshold 


  1. 1.
    Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UKGoogle Scholar
  2. 2.
    Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, de Laet C, Jonsson B (2000) Long-term risk of osteoporotic fractures in Malmo. Osteoporis Int 11:669–674CrossRefGoogle Scholar
  3. 3.
    Melton LJ 3rd (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139–1141CrossRefPubMedGoogle Scholar
  4. 4.
    Kanis JA, Burlet N, Cooper C, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMedGoogle Scholar
  5. 5.
    Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM et al (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239–254CrossRefPubMedGoogle Scholar
  6. 6.
    Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMedGoogle Scholar
  7. 7.
    Hui SL, Slemenda CW, Johnston CC (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809CrossRefPubMedGoogle Scholar
  8. 8.
    Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995CrossRefPubMedGoogle Scholar
  9. 9.
    Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMedGoogle Scholar
  10. 10.
    Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporosis Int 13:527–536CrossRefGoogle Scholar
  11. 11.
    De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338CrossRefPubMedGoogle Scholar
  12. 12.
    Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefPubMedGoogle Scholar
  13. 13.
    Kanis JA, Johansson H, Oden A et al (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029–1037CrossRefPubMedGoogle Scholar
  14. 14.
    Kanis JA, Johnell O, Oden A et al (2006) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162CrossRefGoogle Scholar
  15. 15.
    Kanis JA, Johansson H, Oden A et al (2000) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899CrossRefGoogle Scholar
  16. 16.
    Kanis JA, Johansson H, Johnell O et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742CrossRefPubMedGoogle Scholar
  17. 17.
    Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046CrossRefPubMedGoogle Scholar
  18. 18.
    Kanis JA, Johnell O, De Laet C, Jonnson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probability: implications for risk assessment. J Bone Miner Res 17:1237–1244CrossRefPubMedGoogle Scholar
  19. 19.
    World Health Organization (2007) Assessment of osteoporosis at the primary health care level. Summary Report of a WHO Scientific Group. WHO, Geneva, www.who.int/chp/topics/rheumatic/en/index.html Google Scholar
  20. 20.
    Kanis JA, McCloskey EV, Johansson H, the National Osteoporosis Guideline Group (2009) Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408, Erratum published 2009 Osteoporos Int 20, 499-502CrossRefGoogle Scholar
  21. 21.
    Siminoski K, Leslie WD, Frame H et al (2007) Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10:120–123CrossRefPubMedGoogle Scholar
  22. 22.
    Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A et al (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429–448CrossRefPubMedGoogle Scholar
  23. 23.
    Kurth AA, Pfeilschifter J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36:683–90, GermanCrossRefPubMedGoogle Scholar
  24. 24.
    Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458CrossRefPubMedGoogle Scholar
  25. 25.
    Siris E, Delmas PD (2008) Assessment of 10-year absolute risk: a new paradigm with worldwide application. Osteoporos Int 19:383–384CrossRefPubMedGoogle Scholar
  26. 26.
    Johansson H, Kanis JA, Borgström F, Ström O, Svensson O, Mellström D (2010) FRAX® ett stöd för frakturprevention. Läkartidningen, in pressGoogle Scholar
  27. 27.
    Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, LondonGoogle Scholar
  28. 28.
    Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London, UKGoogle Scholar
  29. 29.
    Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, London, UKGoogle Scholar
  30. 30.
    Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15CrossRefPubMedGoogle Scholar
  31. 31.
    Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256Google Scholar
  32. 32.
    Kanis JA, Johnell O, on behalf of the Committee of Scientific Advisors of the International Osteoporosis Foundation (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238CrossRefPubMedGoogle Scholar
  33. 33.
    National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset (2008) Osteoporosis: clinical guideline for prevention and treatment. University of Sheffield Press, SheffieldGoogle Scholar
  34. 34.
    Tsang SWY, Kanis KAWC, JA JH, Oden A (2009) Ten-year fracture probability in Hong Kong southern Chinese according to age and BMD femoral neck T-scores. Osteoporos Int 20:1939–1945CrossRefPubMedGoogle Scholar
  35. 35.
    Czerwiński E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J (2007) Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 9:337–356PubMedGoogle Scholar
  36. 36.
    Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–390CrossRefPubMedGoogle Scholar
  37. 37.
    Neuprez A, Johansson H, Kanis JA et al (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64:612–619PubMedGoogle Scholar
  38. 38.
    National Osteoporosis Foundation (NOF) (2008) Clinician’s Guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, National Osteoporosis Foundation Washington www.nof.org
  39. 39.
    Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMedGoogle Scholar
  40. 40.
    Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London, CHMPGoogle Scholar
  41. 41.
    McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double blind, placebo controlled randomised study. Osteoporos Int 20:811–818CrossRefPubMedGoogle Scholar
  42. 42.
    Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®. Bone 44:49–54Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  • J. A. Kanis
    • 1
  • E. V. McCloskey
    • 1
    • 2
  • H. Johansson
    • 1
  • A. Oden
    • 1
  • O. Ström
    • 1
  • F. Borgström
    • 1
  1. 1.WHO Collaborating Centre for Metabolic Bone DiseasesUniversity of Sheffield Medical SchoolSheffieldUK
  2. 2.Osteoporosis CentreNorthern General HospitalSheffieldUK

Personalised recommendations